A Phase 2, Single Arm, Multicohort, Open Label, Multicenter Trial of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Patients With High-risk Myeloid Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SAR 445419 (Primary) ; Cyclophosphamide; Mycophenolate mofetil; Tacrolimus
Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Sponsors Sanofi

Most Recent Events

04 Mar 2024 Planned End Date changed from 17 Feb 2027 to 11 Oct 2027.
04 Mar 2024 Planned primary completion date changed from 17 Feb 2027 to 12 Feb 2027.
04 Mar 2024 Planned initiation date changed from 23 Feb 2024 to 8 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight